Afstyla Market Report 2026

Afstyla Market Overview

• The Afstyla market growth in the historic period has been driven by diagnosis of hemophilia a, adoption of factor replacement therapy • Market expansion is supported by growth in prophylactic treatment adoption, rising pediatric diagnosis rates • Growth Driver: Rising Incidence Of Hemophilia A Drives Growth In The Afstyla Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Afstyla Market?

Afstyla is a medication used to manage hemophilia A, a bleeding disorder caused by a deficiency of clotting factor VIII. It is administered intravenously and requires preparation before use, which helps prevent or treat bleeding episodes by replacing this essential clotting factor in the blood. The main types of formulation in afstyla are lyophilized powder and liquid formulations. Lyophilized powder formulations are freeze-dried versions of medications that, when reconstituted with a liquid, form a usable solution and lyophilized powder formulations offer convenience and stability for patients requiring hemophilia treatment. The clinical indications include prophylactic treatment, on-demand treatment with distribution channels such as hospitals and clinics, and retail and specialty pharmacies. The end users include adult patients, pediatric patients, and geriatric patients.

What Is The Afstyla Market Growth Forecast?

The growth in the forecast period can be attributed to growth in prophylactic treatment adoption, rising pediatric diagnosis rates, advancements in recombinant manufacturing, increased homecare utilization, expansion in emerging markets. Major trends in the forecast period include increasing use of recombinant factor viii therapies, growth of prophylactic hemophilia treatment, rising focus on bleed prevention, expansion of home based infusion therapy, improved treatment adherence through dosing flexibility.

Global Afstyla Market Segmentation

1) By Formulation: Lyophilized Powder, Liquid Formulations 2) By Clinical Indication: Prophylactic Treatment, On-Demand Treatment 3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 4) By End User: Adult Patients, Pediatric Patients, Geriatric Patients

What Are The Drivers Of The Afstyla Market?

An increasing incidence of hemophilia A is expected to propel the growth of the afstyla market going forward. Hemophilia A is a genetic condition characterized by a deficiency of clotting factor VIII, resulting in prolonged bleeding. The growing incidence of hemophilia A can be attributed to improved diagnosis, better reporting and awareness, genetic predisposition, and changing environmental factors. Afstyla helps manage the increasing incidence of hemophilia A by providing long-acting treatment that improves adherence, quality of life, and cost-efficiency. For instance, in April 2024, according to a report published by the World Federation of Hemophilia, a Canada-based international non-profit organization, in 2023, the number of newly identified persons with bleeding disorders (PWBDs) in PACT countries totaled 7,054, including 5,188 individuals with hemophilia. The target number of identified patients is projected to reach 18,832 by 2025. Therefore, an increasing incidence of hemophilia A is driving the afstyla industry. Rising healthcare expenditure is expected to propel the growth of the afstyla market going forward. Healthcare expenditure refers to the total amount spent on goods and services, including personal health care, preventive services, and public health activities, to improve health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Rising healthcare expenditure will fuel the demand growth of Afstyla by increasing access to advanced treatments and enabling more patients to afford specialized care for hemophilia. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rising healthcare expenditure is driving the afstyla industry. The increasing adoption of personalized medicine is expected to drive the growth of the afstyla market going forward. Personalized medicine is a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment rather than using a one-size-fits-all method. Personalized medicine is increasing due to advances in genetic testing that allow treatments to be tailored to individual patient profiles. Afstyla serves as personalized medicine by providing tailored factor VIII replacement therapy based on an individual patient’s specific bleeding control needs. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the afstyla industry.

Key Players In The Global Afstyla Market

Major companies operating in the afstyla market are CSL Behring LLC.

Regional Insights

North America was the largest region in the afstyla market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Afstyla Market?

The afstyla market consists of sales of recombinant factor VIII vials and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Afstyla Market Report 2026?

The afstyla market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the afstyla industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.